Education
About Us
Working with TipRanks
Follow Us
Unity Biotechnology, Inc. (UNBX)
:UNBX
UNBX Stock Chart & Stats
$0.06
$0.00(0.00%)
―
--
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsUBX1325 demonstrated vision gains comparable and statistically non-inferior to aflibercept at week 36 considering difficult to-treat DME patients with favorable safety and tolerability.
Subgroup PerformanceUBX1325 generally outperformed aflibercept in the pre-specified subgroup entering the study with CST <400 microns, reflecting 60% of enrolled patients.
Treatment EfficiencyApproximately 40% of UBX1325 patients did not require supplemental anti-VEGF through week 36, supporting the novel retinal mechanism.
Bears Say
Clinical Study EndpointThe previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.
Patient Group ImbalanceThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.
Unity Biotechnology News
UNBX FAQ
What was Unity Biotechnology, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Unity Biotechnology, Inc.’s market cap?
Currently, no data Available
When is Unity Biotechnology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Unity Biotechnology, Inc.’s earnings last quarter?
Currently, no data Available
Is Unity Biotechnology, Inc. overvalued?
According to Wall Street analysts Unity Biotechnology, Inc.’s price is currently Undervalued.
Does Unity Biotechnology, Inc. pay dividends?
Unity Biotechnology, Inc. does not currently pay dividends.
What is Unity Biotechnology, Inc.’s EPS estimate?
Unity Biotechnology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unity Biotechnology, Inc. have?
Currently, no data Available
What happened to Unity Biotechnology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Unity Biotechnology, Inc.?
Currently, no hedge funds are holding shares in UNBX
Company Description
Unity Biotechnology, Inc.
Unity Biotechnology (UBX) is a biotechnology company focused on developing therapeutics to treat age-related diseases. The company's primary aim is to extend healthspan, the period during which individuals remain healthy and free from age-related ailments. Unity Biotechnology's core products target senescent cells, which are cells that have stopped dividing and can contribute to various age-related diseases. By focusing on senescence biology, Unity seeks to develop innovative treatments for conditions such as osteoarthritis and other chronic diseases associated with aging.